FORWARD I: A Phase III Study of Mirvetuximab Soravtansine Versus Chemotherapy in Platinum-Resistant Ovarian Cancer

References

• Ferlay J , SoerjomataramI, DikshitRet al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer136(5), e359–e386 (2015).
   PubMed Web of Science ®Google Scholar
• Reid BM , PermuthJB, SellersTA. Epidemiology of ovarian cancer: a review. Cancer Biol. Med.14(1), 9–32 (2017).
   PubMed Web of Science ®Google Scholar
• Lacey JV , ShermanME. Ovarian neoplasia. In: Robboy’s Pathology of the Female Reproductive Tract. RobboySL, MutterGL, PratJ ( Eds). Churchill Livingstone, Elsevier, Oxford, UK, 601 (2009).
   Google Scholar
• Desai A , XuJ, AysolaKet al. Epithelial ovarian cancer: an overview. World J. Transl. Med.3(1), 1–8 (2014).
   PubMedGoogle Scholar
• Davis A , TinkerAV, FriedlanderM. ‘Platinum resistant’ ovarian cancer: what is it, who to treat and how to measure benefit?Gynecol. Oncol.133(3), 624–631 (2014).
   PubMed Web of Science ®Google Scholar
• Markman M , BookmanMA. Second-line treatment of ovarian cancer. Oncologist5(1), 26–35 (2000).
   PubMedGoogle Scholar
• Luvero D , MilaniA, LedermannJA. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther. Adv. Med. Oncol.6(5), 229–239 (2014).
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E , HilpertF, WeberBet al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized Phase III trial. J. Clin. Oncol.32(13), 1302–1308 (2014).
   PubMed Web of Science ®Google Scholar
• Poveda AM , SelleF, HilpertFet al. Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized Phase III AURELIA trial. J. Clin. Oncol.33(32), 3836–3838 (2015).
   PubMed Web of Science ®Google Scholar
• Pistollato F , Calderon IglesiasR, RuizRet al. The use of natural compounds for the targeting and chemoprevention of ovarian cancer. Cancer Lett.411, 191–200 (2017).
   PubMed Web of Science ®Google Scholar
• Liu J , MatulonisUA. New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances. Clin. Cancer Res.20(20), 5150–5156 (2014).
   PubMed Web of Science ®Google Scholar
• Della Pepa C , ToniniG, PisanoCet al. Ovarian cancer standard of care: are there real alternatives? Chin. J. Cancer 34(1), 17–27 (2015).
   PubMed Web of Science ®Google Scholar
• Colombo N , ContePF, PignataS, RaspagliesiF, ScambiaG. Bevacizumab in ovarian cancer: focus on clinical data and future perspectives. Crit. Rev. Oncol. Hematol.97, 335–348 (2016).
   PubMed Web of Science ®Google Scholar
• Konecny GE , KristeleitRS. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. Br. J. Cancer115(10), 1157–1173 (2016).
   PubMed Web of Science ®Google Scholar
• Vergote IB , MarthC, ColemanRL. Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications. Cancer Metastasis Rev.34(1), 41–52 (2015).
   PubMed Web of Science ®Google Scholar
• Choi SW , MasonJB. Folate and carcinogenesis: an integrated scheme. J. Nutr.130(2), 129–132 (2000).
   PubMed Web of Science ®Google Scholar
• Kalli KR , ObergAL, KeeneyGLet al. Folate receptor α as a tumor target in epithelial ovarian cancer. Gynecol. Oncol.108(3), 619–626 (2008).
   PubMed Web of Science ®Google Scholar
• Markert S , LassmannS, GabrielBet al. Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue. Anticancer Res.28(6A), 3567–3572 (2008).
   PubMed Web of Science ®Google Scholar
• O’Shannessy DJ , SomersEB, SmaleR, FuYS. Expression of folate receptor-α (FRA) in gynecologic malignancies and its relationship to the tumor type. Int. J. Gynecol. Pathol.32(3), 258–268 (2013).
   PubMed Web of Science ®Google Scholar
• Toffoli G , RussoA, GalloAet al. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int. J. Cancer79(2), 121–126 (1998).
   PubMed Web of Science ®Google Scholar
• Marchetti C , PalaiaI, GiorginiMet al. Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review. Onco Targets Ther.7, 1223–1236 (2014).
   PubMed Web of Science ®Google Scholar
• Assaraf YG , LeamonCP, ReddyJA. The folate receptor as a rational therapeutic target for personalized cancer treatment. Drug Resist. Updat.17(4–6), 89–95 (2014).
   PubMed Web of Science ®Google Scholar
• Ledermann JA , CanevariS, ThigpenT. Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments. Ann. Oncol.26(10), 2034–2043 (2015).
   PubMed Web of Science ®Google Scholar
• Vergote I , ArmstrongD, ScambiaGet al. A randomized, double-blind, placebo-controlled, Phase III study to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse. J. Clin. Oncol.34(19), 2271–2278 (2016).
   PubMed Web of Science ®Google Scholar
• Levin J . Merck and endocyte announce independent DSMB recommends vintafolide PROCEED Phase III trial be stopped for futility following interim analysis. FierceBiotech (2014). www.fiercebiotech.com/biotech/merck-and-endocyte-announce-independent-dsmb-recommends-vintafolide-proceed-phase-3-trial.
   Google Scholar
• Chari RV , MillerML, WiddisonWC. Antibody–drug conjugates: an emerging concept in cancer therapy. Angew. Chem. Int. Ed. Engl.53(15), 3796–3827 (2014).
   PubMed Web of Science ®Google Scholar
• Parslow AC , ParakhS, LeeFT, GanHK, ScottAM. Antibody–drug conjugates for cancer therapy. Biomedicines4(3), e254–e262 (2016).
   Google Scholar
• Thomas A , TeicherBA, HassanR. Antibody–drug conjugates for cancer therapy. Lancet Oncol.17(6), e254–e262 (2016).
   PubMed Web of Science ®Google Scholar
• Lambert JM , MorrisCQ. Antibody–drug conjugates (ADCs) for personalized treatment of solid tumors: a review. Adv. Ther.34(5), 1015–1035 (2017).
   PubMed Web of Science ®Google Scholar
• Lambert JM , BerkenblitA. Antibody–drug conjugates for cancer treatment. Annu. Rev. Med.17(6), e254–e262 (2017).
   Google Scholar
• Gunderson CC , MooreKM. Mirvetuximab soravtansine. Folate receptor α (FR-α)-targeting antibody drug conjugate, treatment of epithelial ovarian cancer. Neoplasia18(12), 775–784 (2016).
   PubMed Web of Science ®Google Scholar
• Oroudjev E , LopusM, WilsonLet al. Maytansinoid–antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol. Cancer Ther.9(10), 2700–2713 (2010).
   PubMed Web of Science ®Google Scholar
• Goldmacher VS , AudetteCA, GuanYet al. High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction. PLoS ONE10(2), e0117523 (2015).
   PubMed Web of Science ®Google Scholar
• Kovtun YV , AudetteCA, YeYet al. Antibody–drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res.66(6), 3214–3221 (2006).
   PubMed Web of Science ®Google Scholar
• Ab O , WhitemanKR, BartleLMet al. IMGN853, a folate receptor-α (FR-α)-targeting antibody–drug conjugate, exhibits potent targeted antitumor activity against FR-α-expressing tumors. Mol. Cancer Ther.14(7), 1605–1613 (2015).
   PubMed Web of Science ®Google Scholar
• Ponte JF , AbO, LanieriLet al. Mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody–drug conjugate, potentiates the activity of standard of care therapeutics in ovarian cancer models. Neoplasia18(12), 775–784 (2016).
   PubMed Web of Science ®Google Scholar
• Moore KN , BorghaeiH, O’MalleyDMet al. Phase I dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody–drug conjugate, in patients with solid tumors. Cancer123(16), 3080–3087 (2017).
   PubMed Web of Science ®Google Scholar
• Eaton JS , MillerPE, MannisMJ, MurphyCJ. Ocular adverse events associated with antibody–drug conjugates in human clinical trials. J. Ocul. Pharmacol. Ther.31(10), 589–604 (2015).
   PubMed Web of Science ®Google Scholar
• Martin LP , KonnerJA, MooreKNet al. Characterization of folate receptor α (FR-α) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a Phase I expansion study of the FR-α-targeting antibody–drug conjugate mirvetuximab soravtansine. Gynecol. Oncol.147(2), 402–407 (2017).
   PubMed Web of Science ®Google Scholar
• Moore KN , MartinLP, O’MalleyDMet al. Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Phase I expansion study. J. Clin. Oncol.35(10), 1112–1118 (2017).
   PubMed Web of Science ®Google Scholar
• Moore KN , MatulonisUA, O’MalleyDMet al. Mirvetuximab soravtansine (IMGN853), a folate alpha (FR-α)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian caner (EOC) patients (pts): activity and safety analyses in Phase I pooled expansion cohorts. J. Clin. Oncol.35(Suppl.), Abstract 5547 (2017).
   Google Scholar
• Marupudi NI , HanJE, LiKW, RenardVM, TylerBM, BremH. Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin. Drug Saf.6(5), 609–621 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenberg P , AnderssonH, BomanKet al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol.41(5), 418–424 (2002).
   PubMed Web of Science ®Google Scholar
• Markman M , HallJ, SpitzDet al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J. Clin. Oncol.20(9), 2365–2369 (2002).
   PubMed Web of Science ®Google Scholar
• Gynecologic Oncology Group , MarkmanM, BlessingJet al.Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol. Oncol.101(3), 436–440 (2006).
   PubMed Web of Science ®Google Scholar
• Baird RD , TanDS, KayeSB. Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nat. Rev. Clin. Oncol.7(10), 575–582 (2010).
   PubMed Web of Science ®Google Scholar
• Markman M . Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer. Cancer Manag. Res.3, 219–225 (2011).
   PubMedGoogle Scholar
• Markman M , KennedyA, WebsterK, PetersonG, KulpB, BelinsonJ. Phase II trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol. Oncol.78(3 Pt 1), 369–372 (2000).
   PubMed Web of Science ®Google Scholar
• Wilailak S , LinasmitaV. A study of pegylated liposomal doxorubicin in platinum-refractory epithelial ovarian cancer. Oncology67(3–4), 183–186 (2004).
   PubMed Web of Science ®Google Scholar
• Nakayama M , KobayashiH, TakaharaT, NishimuraY, FukushimaK, YoshizawaK. A comparison of overall survival with 40 and 50 mg/m2 pegylated liposomal doxorubicin treatment in patients with recurrent epithelial ovarian cancer: propensity score-matched analysis of real-world data. Gynecol. Oncol.143(2), 246–251 (2016).
   PubMed Web of Science ®Google Scholar
• Sehouli J , Oskay-OzcelikG. Current role and future aspects of topotecan in relapsed ovarian cancer. Curr. Med. Res. Opin.25(3), 639–651 (2009).
   PubMed Web of Science ®Google Scholar
• Sehouli J , StengelD, HarterPet al. Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter Phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J. Clin. Oncol.29(2), 242–248 (2011).
   PubMed Web of Science ®Google Scholar